AiCubator

A new way of collaboration in the field of anti-infectives

Often, it is not the lack of groundbreaking ideas that prevents the development of novel, innovative anti-infective drugs. Rather, a lack of funding, development and business experience limits resources for start-ups and scientific groups, discouraging the development of new therapeutic options. AiCuris strongly believes that there is a need to encourage the development of more early projects based on new scientific principles to fill pipeline gaps, tackle AMR and prevent future pandemics. Therefore, we are constantly searching for novel technologies and creative approaches to develop more effective treatments against infectious diseases with high medical needs.

 

Converting Great ideas into Reality

To promote early ideas that might lead to the next resistant breaking antibiotic or anti-infective, AiCuris has launched the AiCubator, an innovative corporate incubator that provides long-term support (up to 3 years) for such anti-infective research projects.

Winners of the Resident Status 2020

Every year AiCuris selects up to three projects that are scientifically attractive but too early staged for licensing deals. These projects should focus on areas of high priority in the field of anti-infectives.

Prokaryotics Inc., USA

Prokaryotics Inc., USA

Prokaryotics Inc., USA (a spin-out from from Merck & Co., Inc.) aim to develop a new antibiotic that targets the fundamentally essential biochemical assembly components of the Gram-negative outer membrane, an intrinsic barrier that naturally restricts antibiotic entry and ultimate efficacy. The most promising enzymes target for drug development in this regard is LspA.

Selmod SA

Selmod SA

Selmod SA, Switzerland have developed a novel class of gyrase inhibitors addressing the known target but overcoming fluoroquinolones resistance. With a lead candidate and three further candidates with a broad spectrum of activity against Gram-negative bacteria, Selmod’s project promises to be an innovative approach as a resistance breaking antibiotic.

University of Essen

University of Essen

The University of Essen, Germany have discovered in preclinical studies that specific forms of interferons are more efficient than the standard treatment. Based on that they engineered chimeric interferons with increased antiviral activity. These interferons could improve efficacy of future HBV therapy as well as protection from various viruses, including future pandemics.

Application for the AiCubator

  • You are an academic group or a recently formed biotech start-up with early-stage projects in the antiviral or antibacterial field?
  • You have invented a new breakthrough mechanism of action with supporting data?
  • You want this data to become a reality?
  • You need support and guidance on your way?

We encourage you to apply for AiCubator resident status during our next call for projects to be started in September 2021. and to get an expert evaluation and support from one of the leaders in anti-infectives in topics such as pre-clinical and clinical drug development and insight into the pharmaceutical business.

Download project selection criteria for our 2020 call.

If you have additional questions, please contact us.

Contact